Terms: = Skin cancer AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306 AND Treatment
9 results:
1. Patterns of care and outcome of cic-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
Brahmi M; Gaspar N; Gantzer J; Toulmonde M; Boudou-Rouquette P; Bompas E; Firmin N; Valentin T; Cancel M; Duffaud F; Bertucci F; Perrin C; Dufresne A; Marec-Bérard P; Jean-Denis M; Ray-Coquard I; Le Loarer F; Pierron G; Tirode F; Blay JY; Watson S
Cancer Med; 2023 Apr; 12(7):7801-7807. PubMed ID: 36537582
[TBL] [Abstract] [Full Text] [Related]
2. Undifferentiated round cell sarcomas with cic-DUX4 gene fusion: expanding the clinical spectrum.
Brčić I; Brodowicz T; Cerroni L; Kashofer K; Serbanescu GL; Kasseroler MT; Amann G; Scheipl S; Szkandera J; Leithner A; Liegl-Atzwanger B
Pathology; 2020 Feb; 52(2):236-242. PubMed ID: 31870501
[TBL] [Abstract] [Full Text] [Related]
3. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract] [Full Text] [Related]
4. The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells.
Shidal C; Inaba JI; Yaddanapudi K; Davis KR
Oncotarget; 2017 Apr; 8(15):25525-25541. PubMed ID: 28424421
[TBL] [Abstract] [Full Text] [Related]
5. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells.
Shidal C; Al-Rayyan N; Yaddanapudi K; Davis KR
Oncotarget; 2016 Dec; 7(51):84128-84141. PubMed ID: 27566591
[TBL] [Abstract] [Full Text] [Related]
6. [Case report: Acro-necrosis of the upper limbs caused by gemcitabine therapy].
D'Alessandro V; Errico M; Varriale A; Greco A; De Cata A; Carnevale V; Grilli M; De Luca P; Brucoli I; Susi M; Camagna A
Clin Ter; 2003; 154(3):207-10. PubMed ID: 12910811
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.
Bukh A; Møller-Larsen A; Aguado MT; Møller-Larsen F; Møller NP
Cancer Immunol Immunother; 1988; 26(3):280-4. PubMed ID: 3260134
[TBL] [Abstract] [Full Text] [Related]
8. Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Wong JH; Aguero B; Gupta RK; Morton DL
Cancer Immunol Immunother; 1988; 27(2):142-6. PubMed ID: 3046746
[TBL] [Abstract] [Full Text] [Related]
9. Circulating immune complexes in malignant melanoma: serial studies in 130 patients.
Bharwani N; Campbell L; Ashley P; Queen WD; Phillips TM; Jerry LM
Oncology; 1986; 43(3):143-8. PubMed ID: 3703459
[TBL] [Abstract] [Full Text] [Related]
